June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Correlation between the Inflammatory Marker HLA DR and Signs and Symptoms in moderate to severe Dry Eye Disease
Author Affiliations & Notes
  • Christophe Baudouin
    Ophthalmology, Quinze-Vingts Hospital, Paris, France
  • Hong Liang
    Ophthalmology, Quinze-Vingts Hospital, Paris, France
  • Luisa RIANCHO
    Institut de la Vision, Paris, France
  • Dahlia Ismail
    Santen SAS, Evry, France
  • Maeva Deniaud
    MDSTAT, Paris, France
  • Mourad Amrane
    Santen SAS, Evry, France
  • Francoise Brignole-Baudouin
    Institut de la Vision, Paris, France
  • Footnotes
    Commercial Relationships Christophe Baudouin, Alcon (C), Allergan (C), Santen (C), Thea (C); Hong Liang, Santen (F); Luisa RIANCHO, None; Dahlia Ismail, Santen SAS (E); Maeva Deniaud, Santen SAS (C); Mourad Amrane, Santen SAS (E); Francoise Brignole-Baudouin, Allergan (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 298. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christophe Baudouin, Hong Liang, Luisa RIANCHO, Dahlia Ismail, Maeva Deniaud, Mourad Amrane, Francoise Brignole-Baudouin; Correlation between the Inflammatory Marker HLA DR and Signs and Symptoms in moderate to severe Dry Eye Disease. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):298.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

From dry eye (DE) clinical studies, it is recognized that signs and symptoms are not well correlated. Flow cytometric HLA-DR analysis of conjunctival imprints (CI) was used to assess ocular surface inflammation in many clinical studies. Here, we retrospectively analyzed correlations between clinical signs and symptoms, and conjunctival HLA-DR in 3 phase III clinical studies conducted on moderate to severe DE-patients in several European countries.


Demographic and baseline DE characteristics were analyzed (mainly, corneal fluorescein staining (CFS), Schirmer test, tear break‑up time (TBUT), tear osmolarity, Ocular Surface Disease Index (OSDI®) and Visual Analog Scale (VAS) scores). CI were collected from 311 patients using a polyether-sulfone filter. After extraction and dispersion in fluid, cells were stained with an anti-human HLA-DR alpha-chain (Dako) and HLA-DR fluorescence was quantified using QIFIKIT (Dako) calibrated beads in arbitrary units of fluorescence (AUF).


In DE-patients, HLA-DR significantly increased in Sjögren’s syndrome (p<0.0001) and meibomian gland disease (p=0.0223). HLA-DR AUF was correlated positively with CFS (r=0.30, p<0.0001) and negatively with Schirmer test (r=-0.20, p=0.0003) and TBUT (r=-0.13, p=0.0226). Moreover, correlations were also found significant with the OSDI® and the VAS scores (r=0.12, p=0.0426 and r=0.14, p=0.0176, respectively). HLA‑DR AUF and osmolarity were not correlated (r=0.08, p=0.4987).


In clinical research on dry eye, the lack of correlations between symptoms and signs sometimes observed makes data interpretation somewhat complicated. Here we demonstrated for the first time that the inflammatory marker HLA-DR assessed using a flow cytometry method correlated significantly with the clinical signs (CFS, Schirmer test and TBUT) and with the symptom questionnaires. HLA DR used for about 20 years to assess ocular surface inflammation could be considered today as a surrogate biomarker bridging signs and symptoms in clinical investigations of dry eye disease.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.